Vor Biopharma (VOR) Depreciation & Amortization (CF) (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $28000.0 in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 96.5% year-over-year to $28000.0 in Q1 2026; TTM through Mar 2026 was $2.2 million, a 36.29% decrease from a year earlier, with the FY2025 full-year figure at $2.9 million, down 17.14% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $28000.0, down from $36000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for VOR reached as high as $2.1 million in Q2 2025 and fell as low as $2000.0 in Q3 2025.
• Historically, Depreciation & Amortization (CF) has averaged $739000.0 across 5 years, with a median of $837000.0 in 2023.
• Across the five-year window, Depreciation & Amortization (CF) surged 200.0% in 2022 and tumbled 99.78% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $625000.0 in 2022, then soared by 42.72% to $892000.0 in 2023, then declined by 10.31% to $800000.0 in 2024, then plunged by 95.5% to $36000.0 in 2025, then dropped by 22.22% to $28000.0 in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $28000.0 in Q1 2026, $36000.0 in Q4 2025, and $2000.0 in Q3 2025.